The GTPBP3 Knockout NCI-H1975 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma cell line. This population is engineered for constitutive disruption of the GTPBP3 gene, which encodes a mitochondrial GTPase essential for post-transcriptional modification of mitochondrial transfer RNAs (mt-tRNAs). As a polyclonal knockout pool, this model provides a heterogeneous loss-of-function system suitable for population-level analyses of mitochondrial translation deficits and their downstream consequences, without selecting for single-cell clones. The product serves as a reproducible starting point for investigating mitochondrial gene expression regulation in a disease-relevant cancer background.
The host NCI-H1975 cell line is a well-established non-small cell lung cancer (NSCLC) model derived from the pleural effusion of a nonsmoking female patient with lung adenocarcinoma. These epithelial cells harbor both EGFR L858R and T790M mutations, conferring oncogenic signaling and acquired resistance to first-generation tyrosine kinase inhibitors. Thus, NCI-H1975 is widely used to study EGFR-driven tumor biology, drug sensitivity, and resistance mechanisms. The integration of a mitochondrial translation-focused knockout into this oncogenic context enables exploration of the interplay between mitochondrial function and kinase-addicted cancer metabolism.
GTPBP3 functions as a catalytic subunit in the heterodimeric enzyme complex with MTO1, catalyzing 5-taurinomethyluridine (??m5U) modification at the wobble position of specific mt-tRNAs, including those for Leu(UUR), Lys, Glu, and Gln. This modification ensures accurate codon-anticodon pairing and processive elongation during mitochondrial protein synthesis. Consequently, GTPBP3 activity is indispensable for translation of mitochondrially encoded respiratory chain subunits such as MT-CO1, MT-CO2, MT-ND1, and MT-CYTB, which are core components of complexes I, III, IV, and V. Upstream, GTPBP3 expression is regulated by transcription factors TFAM and PGC-1??, which coordinate mitochondrial biogenesis, and is influenced by mTORC1 signaling, linking nutrient sensing to mitochondrial translation capacity. Interacting partners include MTO1, TRMU, and the mitochondrial ribosome, while the post-transcriptional modification pathway broadly interfaces with oxidative phosphorylation (OXPHOS) and respiratory chain complex assembly.
In the NCI-H1975 background, GTPBP3 disruption creates a unique model to study how mitochondrial translation insufficiency reshapes cancer cell metabolism. Lung adenocarcinoma cells frequently exhibit metabolic plasticity, and impaired OXPHOS due to defective mt-tRNA modification can trigger compensatory glycolytic upregulation, alter redox homeostasis, or activate mitochondrial retrograde signaling. This knockout system may reveal vulnerabilities associated with combined OXPHOS deficiency, such as synthetic lethality with inhibitors of glycolysis, glutaminolysis, or autophagy. Furthermore, the EGFR-mutant setting allows investigation of how mitochondrial dysfunction modulates responses to targeted therapies, potentially informing strategies to overcome drug resistance through metabolic intervention.
Researchers can employ these polyclonal knockout cells in diverse assays to dissect mitochondrial biology in lung cancer. Common applications include measuring oxygen consumption rate (OCR) via Seahorse analyzers to quantify OXPHOS impairment, performing ATP production assays, and analyzing mitochondrial translation efficiency through pulse-chase labeling with 35S-methionine. Respiratory chain subunit expression can be evaluated by Western blotting for MT-CO1 and MT-CO2, while mt-tRNA modification status may be examined by mass spectrometry. Functional studies such as colony formation assays and drug sensitivity testing under OXPHOS-stressed conditions are also facilitated. This knockout model supports investigations into mitochondrial disease mechanisms, metabolic adaptation, and therapeutic targeting of mitochondrial vulnerabilities. For further information or custom requirements, please contact Ascent Research.
